Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Geriatrics Oncology
•
Supportive Care
How do you mitigate cognitive slowing in elderly patients with mCSPC receiving LHRH agonist therapy?
Do you switch medications or offer adjunct therapies? What works well in your practice?
Related Questions
If a patient diagnosed with seminoma after orchiectomy has margin positive disease noted in the spermatic cord and no overt metastasis on imaging and normal tumor markers, how should this patient be staged?
What perioperative systemic therapy would you use for a patient with oligometastatic clear cell RCC with a bony metastasis at risk for fracture?
Do you offer prostate RT to men with 0-3 bone metastases on conventional imaging when PSMA PET shows a very high number of M1 lesions?
Is there any way to safely treat patients with mCRPC with 177-Lu PSMA who are on hemodialysis?
How do you manage prostate cancer in patients that cannot swallow pills?
Would you offer neoadjuvant chemotherapy prior to trimodality therapy in a fit patient who refuses surgery for muscle-invasive bladder cancer?
Can defibrotide be given safely for VOD in patients with refractory thrombocytopenia to platelet transfusions?
Would the occurrence of obvious tumor rupture/spillage intraoperatively impact your decision for adjuvant systemic therapy after resection of either clear cell RCC or papillary RCC?
Would you offer adjuvant immunotherapy (pembrolizumab) for chromophobe RCC with R1 resection?
Is there a clinical benefit for a repeat TURBT to ensure complete resection of the bladder tumor prior to neoadjuvant chemotherapy and radical cystectomy?